Spectrum Investment Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$883K Buy
3,508
+196
+6% +$42.2K 0.36% 25
2026
Q1
$720K Buy
3,312
+40
+1% +$8.87K 0.36% 22
2025
Q4
$748K Buy
3,272
+463
+16% +$105K 0.37% 22
2025
Q3
$650K Buy
2,809
+49
+2% +$9.98K 0.35% 21
2025
Q2
$512K Buy
2,760
+10
+0.4% +$1.86K 0.3% 20
2025
Q1
$576K Sell
2,750
-53
-2% -$10.3K 0.37% 19
2024
Q4
$498K Buy
2,803
+78
+3% +$14.3K 0.33% 20
2024
Q3
$538K Buy
2,725
+21
+0.8% +$3.92K 0.37% 18
2024
Q2
$464K Sell
2,704
-399
-13% -$66.1K 0.34% 18
2024
Q1
$565K Buy
3,103
+22
+0.7% +$3.79K 0.42% 22
2023
Q4
$477K Buy
+3,081
New +$449K 0.38% 23

Other funds holding ABBV

Spectrum Investment Advisors's ABBV Position: Q2 2026 in Review

Spectrum Investment Advisors increased its AbbVie (ABBV) stake by 5.9% in Q2 2026, buying an estimated $42.2K and bringing the position to 3,508 shares worth $883K. The position accounts for 0.36% of the portfolio, ranked #25.

Spectrum Investment Advisors first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Spectrum Investment Advisors held 3,508 shares of AbbVie worth $883K as of Q2 2026.
  • Spectrum Investment Advisors bought 196 AbbVie shares in Q2 2026, an estimated $42.2K.
  • AbbVie made up 0.36% of Spectrum Investment Advisors's portfolio in Q2 2026, its #25 holding.
  • Spectrum Investment Advisors first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
  • 4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Spectrum Investment Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.